Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations

被引：0
|
作者：
Wu, L. [1 ]
Pu, X. [2 ]
Zhou, Y. [2 ]
Kong, Y. [2 ]
Chen, B. [2 ]
Yang, A. [3 ]
Li, J. [2 ]
Li, K. [2 ]
Xu, Y. [2 ]
机构：
[1] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[2] Hunan Canc Hosp, Dept Thorac Oncol 2, Changsha, Peoples R China
[3] Hunan Canc Hosp, Dept Radiotherapy, Changsha, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574P
引用
收藏
页码：S1695 / S1695
页数：1
相关论文
共 50 条
  • [21] Aumolertinib in Treatment-Naive EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S397 - S398
  • [22] Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations
    Si Sun
    Chang Liu
    Chunyan Duan
    Songxia Yu
    Qiao Zhang
    Nana Xu
    Bo Yu
    Xianghua Wu
    Jialei Wang
    Xingjiang Hu
    Hui Yu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2937 - 2949
  • [23] Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
    Kaen, D.
    Tsou, F.
    Lupinacci, L.
    Puparelli, C.
    Minatta, J.
    Rizzo, M.
    Berutti, S.
    Di Giovanni, R.
    Ferreira, Y.
    Recondo, G.
    Carranza, O.
    Flores, M.
    Aman, E.
    Di Mario, G.
    Pini, A.
    Castagneris, N.
    Roa, M.
    Enrico, D.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S668
  • [24] A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naive NSCLC patients with EGFR mutation
    Shi, Y-K.
    Zhou, J.
    Zhao, Y.
    Zhu, B.
    Zhang, L.
    Li, X.
    Fang, J.
    Shi, J.
    Zhuang, Z.
    Yang, S.
    Wang, D.
    Yu, H.
    Zhang, L.
    Zheng, R.
    Greco, M.
    Wang, T.
    Mo, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1000 - S1000
  • [25] Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab
    Miwa, Maki
    Okuma, Yusuke
    Kashima, Jumpei
    Hosomi, Yukio
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [26] EFFICACY AND SAFETY OF TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WITH ADVANCED MELANOMA RECEIVING IPILIMUMA
    Ridolfi, R.
    Berman, D.
    Siegel, J.
    Hamid, O.
    Minor, D.
    Amin, A.
    Thompson, J.
    Ron, I.
    Assi, H.
    Weber, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 242 - 242
  • [27] Avapritinib in treatment-naive patients with advanced systemic mastocytosis: PATHFINDER efficacy and safety data
    Radia, Deepti H.
    Gotlib, Jason
    Drummond, Mark W.
    George, Tracy I.
    Lin, Hui-Min
    Dimitrijevic, Sasa
    Munoz-Gonzalez, Javier I.
    Bidollari, Ilda
    Deininger, Michael W.
    DeAngelo, Daniel J.
    Reiter, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 24 - 25
  • [28] Safety and efficacy of dacomitinib for EGFR plus NSCLC in the subgroup of Asian patients from ARCHER 1050
    Mok, T. S. K.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Rosell, R.
    Linke, R.
    Wong, C. H.
    Tang, Y.
    Singh, M.
    Wilner, K. D.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis
    Priantti, Jonathan N.
    Vilbert, Maysa
    Moraes, Francisco Cezar A.
    Michelon, Isabella
    Castro, Caio
    Leighl, Natasha B.
    Cavalcante, Ludimila
    Fujiwara, Yu
    Addeo, Alfredo
    Bar, Jair
    Cortellini, Alessio
    Nassar, Amin
    Naqash, Abdul Rafeh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Topic: Advanced NSCLC Frequency of Uncommon EGFR Mutations in CR
    Porras Gutierrez, R.
    Corrales-Rodriguez, L.
    Abbas, J.
    Mendez, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1189 - S1189
12345